Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deltex Injunction Demonstrates Need For Fast Response To FDA Inspections

This article was originally published in The Tan Sheet

Executive Summary

An injunction prohibiting Deltex Pharmaceuticals from making drugs until it complies with good manufacturing practices and other regulations reminds firms that "the leash may not be as long" under the current FDA as in the past, a health care attorney says.
Advertisement

Related Content

FDA Issues More Warning Letters, Drops Follow-Up Letters In Favor Of Action
FDA Issues More Warning Letters, Drops Follow-Up Letters In Favor Of Action
One-Third Of Supplement GMP Inspections Reveal "Serious Problems" - FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS104809

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel